Search | Clinical Trials Finder

Conditions: Post-acute Corona Virus 19 (COVID-19) (Long COVID)
Interventions: RSLV-132, Sodium Chloride 0.9%; Drug
Lead sponsor: Resolve Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 5
States / cities: Mobile, Alabama • Coral Gables, Florida • Pompano Beach, Florida + 2 more

Conditions: Parkinson's Disease
Interventions: RM-131, Placebo; Drug
Lead sponsor: Motus Therapeutics, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 13
States / cities: Los Angeles, California • Englewood, Colorado • Gainesville, Florida + 10 more

Conditions: Healthy Subjects
Interventions: PeakATP 250, Placebo, PeakATP 400, PeakATP 400 plus proprietary blend; Dietary Supplement
Lead sponsor: Metabolic Technologies Inc.; Industry
Eligibility: 20 Years to 30 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Ames, Iowa

Conditions: Atrial Fibrillation, Cerebrovascular Accident, Death, Sudden
Interventions: Amiodarone, Sotalol; Drug
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: Not listed
Enrollment: 706 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2003
U.S. locations: 28
States / cities: Tucson, Arizona • No. Little Rock, Arkansas • Fresno, California + 25 more

Conditions: Urinary Incontinence
Interventions: solifenacin succinate, Placebo; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 640 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 58
States / cities: Homewood, Alabama • Anchorage, Alaska • Tucson, Arizona + 53 more

Conditions: Heart Failure With Preserved Ejection Fraction
Interventions: AZD4831, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 711 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 21
States / cities: Alexander City, Alabama • Little Rock, Arkansas • Sacramento, California + 18 more

Conditions: Healthy
Interventions: Commercially Available Food Bar, Placebo; Dietary Supplement
Lead sponsor: Texas A&M University; Other
Eligibility: 18 Years to 35 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: College Station, Texas

Conditions: Metabolism, Liver Function, Pharmacokinetics
Interventions: Cannabidiol (CBD) powder formulation, Cannabidiol (CBD) Oil based tincture formulation, Cannabidiol (CBD) Gum Arabic, maltodextrin base formulation, Cannabidiol (CBD) Gum Arabic, sorbitol base formulation, Cannabidiol (CBD) Isolate in water formulation, CBD matching Placebo; Dietary Supplement
Lead sponsor: Colorado State University; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Fort Collins, Colorado

Conditions: NonSegmental Vitiligo
Interventions: Povorcitinib, Placebo; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 467 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 34
States / cities: Hoover, Alabama • Irvine, California • Santa Monica, California + 29 more

Conditions: COPD, COPD Exacerbation, Lung Diseases, Respiratory Disorders, Pulmonary Disease, Chronic Obstructive Lung Diseases, Chronic Obstructive Airway Disease
Interventions: Roflumilast, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years and older
Enrollment: 2,354 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 217
States / cities: Anniston, Alabama • Athens, Alabama • Florence, Alabama + 175 more

Conditions: Pain
Interventions: Relief Product Placebo Control, Relief Active Product 1, Relief Active Product 2, Relief Active Product 3; Dietary Supplement
Lead sponsor: Radicle Science; Industry
Eligibility: 21 Years to 105 Years
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Del Mar, California

Conditions: Resistant Hypertension, Difficult to Control Hypertension
Interventions: MANP, Placebo; Drug
Lead sponsor: E-Star BioTech, LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 5
States / cities: Anniston, Alabama • Tustin, California • DeLand, Florida + 2 more

Conditions: Autophagy, Healthy Aging
Interventions: Spermidine, Placebo; Dietary Supplement
Lead sponsor: Nutraland USA, Inc.; Industry
Eligibility: 40 Years to 70 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Canfield, Ohio

Conditions: Interstitial Cystitis, Bladder Pain Syndrome
Interventions: IW-3300 rectal foam, Placebo; Drug
Lead sponsor: Ironwood Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 53
States / cities: Mobile, Alabama • Scottsdale, Arizona • Tucson, Arizona + 47 more

Conditions: Influenza
Interventions: Cell culture-derived influenza vaccine, Egg-derived influenza virus vaccine, Placebo; Biological
Lead sponsor: Novartis Vaccines; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 11,404 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 17
States / cities: Denver, Colorado • Pembroke Pines, Florida • South Miami, Florida + 13 more

Conditions: OCD, Major Depressive Disorder (MDD), Alcohol Use Disorder (AUD), Healthy Volunteer, Migraine, PTSD, PTSD - Post Traumatic Stress Disorder, Addiction, Tobacco Use Disorder, Obsessive Compulsive Disorder (OCD), Opioid Use Disorder
Interventions: Serotonergic Psychedelic, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Hamden, Connecticut • West Haven, Connecticut

Conditions: Corneal Edema After Cataract Surgery
Interventions: Ripasudil, Placebo; Drug
Lead sponsor: Kowa Research Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 44
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Hemet, California + 37 more

Conditions: Obsessive-Compulsive Disorder
Interventions: N-Acetylcysteine, Placebo; Drug · Other
Lead sponsor: Yale University; Other
Eligibility: 8 Years to 17 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Insulin, Glucose, Healthy Volunteers, Women, Pregnancy
Interventions: Kisspeptin-10, mixed meal tolerance test; Drug · Other
Lead sponsor: Stephanie B. Seminara, MD; Other
Eligibility: 18 Years to 40 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Osteoarthritis, Bilateral Total Knee Arthroplasty
Interventions: Drain, No Drain; Procedure
Lead sponsor: Colorado Joint Replacement; Other
Eligibility: Up to 70 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Gastrointestinal Cancer, Lung Cancer
Interventions: Melatonin, Placebo; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania • Houston, Texas

Conditions: Neurodevelopmental Abnormality
Interventions: Aspirin, Placebo; Drug
Lead sponsor: NICHD Global Network for Women's and Children's Health; Network
Eligibility: 33 Months to 39 Months
Enrollment: 666 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 8
States / cities: Birmingham, Alabama • Denver, Colorado • Newark, Delaware + 5 more

Conditions: Healthy Volunteers
Interventions: PRT064445/Enoxaparin, Placebo/Enoxaparin, Placebo; Combination Product · Drug
Lead sponsor: Portola Pharmaceuticals; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Post Treatment Lyme Syndrome (PTLS), Chronic Pain
Interventions: Milnacipran and D-cycloserine; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 55 Years
Enrollment: 4 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Phase 2 Study of RSLV-132 in Subjects With Long COVID

A Phase 2 Study to Evaluate the Safety and Efficacy of RM-131 in Patients With Parkinson's Disease & Chronic Constipation

Effect of Oral Adenosine-triphosphate (ATP) on Human Muscle Performance

Comparing the Effects of Amiodarone, Sotalol, and Placebo in Maintaining Sinus Rhythm in Patients With Atrial Fibrillation Converted to Sinus Rhythm

A Study to Assess Efficacy and Safety With Solifenacin Succinate to Improve Urinary Continence After Robotic Assisted Radical Prostatectomy

Study to Evaluate the Efficacy and Safety of AZD4831 in Participants With Heart Failure With Left Ventricular Ejection Fraction > 40%

Effects Of Ingesting An Energy Bar On Performance And Recovery

Interaction Between Cannabidiol, Meal Ingestion, and Liver Function

A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)

Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS)

Radicle Relief 24_RLN: A Study Assessing the Impact of Health and Wellness Products on Pain and Related Health Outcomes.

Safety And Tolerability Of Subcutaneous MANP In Difficult To Control/Resistant Hypertensive Subjects

Effects of Miricell Supplementation on Biomarkers of Healthy Aging and Autophagy

A Phase 2 Study of IW-3300 for the Treatment of Bladder Pain in Subjects With Interstitial Cystitis/Bladder Pain Syndrome

Efficacy Study of Two Influenza Vaccines and Placebo in Healthy Adult Subjects

Computer Game, Qualitative, and MEG/EEG Assessment of Serotonergic Psychedelics

A Study to Investigate the Safety and Efficacy of Ripasudil (K-321) Eye Drops After Cataract Surgery

N-acetylcysteine (NAC) for Pediatric Obsessive-Compulsive Disorder

Evaluation of Kisspeptin Glucose-Stimulated Insulin Secretion With Physiologic Mixed Meal Tolerance

Outcomes Following Suction Drain and Non-suction Drain Assisted Total Knee Arthroplasty

Melatonin Versus Placebo and the Effect on Appetite in Advanced Cancer Patients

ASPIRIN: Neurodevelopmental Follow-up Trial

Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 3 of 4)

Uncovering Neural and Immune Mechanisms of Chronic Pain in Post Treatment Lyme Syndrome